



BILLING UPDATE – RSV



October 5, 2023

Dear Childhood Vaccine Program Provider:

This notification is to inform your practice that the monoclonal antibody **nirsevimab** (Beyfortus™) for commercially insured children (non-VFC) under the age of 19 **WILL** be available through the Childhood Vaccine Program (CVP).

- **PLEASE NOTE** that until July 1, 2024, you should **NOT** bill commercial carriers and third-party administrators (TPA) a dosage-based assessment (DBA) for the **nirsevimab** vaccine cost. DBAs are **NOT** required for vaccines until they are published on the *WVA Vaccine Assessment Grid*.
- Your practice should work directly with the patient's insurance carrier or TPA for reimbursement of the administration fee.
- Your practice will still be required to use the V25 Eligibility Code during the [WA DOH eligibility screening process](#).

More information will follow in the spring of 2024 regarding the addition of **nirsevimab** to the *WVA Vaccine Assessment Grid*.

If you have any questions or wish to sign up for the *WA DOH Vaccine Blurb* email list, please contact the WA DOH at WAChildhoodVaccines@doh.wa.gov.

Best regards,

Julia Walter Zell, MA, Esq., Executive Director